Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Acorda Therapeutics announces issuance of additional U.S. Patent for AMPYRA® covering a range of dosage strengths
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Ofatumumab Dose-finding in RRMS Patients
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Antiinflammatory effects of orientin-2″-o-galactopyranoside on lipopolysaccharide-stimulated microglia.
Role of the Blood-Brain Barrier in Multiple Sclerosis.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.
Cross-cultural Adaptation, Reliability, and Validity of the BICAMS in Brazil.
Mitoxantrone for multiple sclerosis.
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-β expression via peroxisome proliferator-activated receptor-α
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
HL-A antigens and multiple sclerosis.
Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.
Study hints of rituximab MS benefit
Optimizing IFN Beta - 1B Dose (Optims)
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Reactive astrocytes as therapeutic targets for CNS disorders.

Pages